KOMPAS.com – The implementation of health protocols and the completion of vaccinations are the two main lines of protection from the Covid-19 pandemic. However, for vulnerable group of Covid-19 additional treatment is required, namely with antibodies monoclonal.
President of the Indonesian Association of Allergy-Immunology (PERALMUNI), Prof. Dr. dr. Iris Rengganis, SpPD, K-AI, FINASIM said the effectiveness of the Covid-19 vaccine in providing protection from infection has continued to decline, especially in people with immunocompromised conditions.
Immunocompromise is a condition of people with a weak immune system or an immune system disorder that makes the body unable to fight off infectious diseases.
Based on data from one study, Iris said the efficacy of the third and third doses of the vaccine in patients with immunocompromised conditions appears to be low.
Iris said protection appeared to decline fastest after two doses of the Covid-19 vaccine in these patients, at an event titled “The Importance of Special Protection for Vulnerable Groups in the Era of the Covid-19 Pandemic,” Thursday ( 11/24/2022).
This vulnerable group is increasingly at risk of being exposed to Covid-19 repeatedly at the same time. This is because the replication of the corona virus that causes Covid-19 is constantly changing.
“Prokes systems and booster vaccinations are the two main protections that can protect people from Covid-19 infection, but for groups vulnerable due to their condition, they need other modalities or options such as immunization therapy passive with monoclonal antibodies,” said Iris.